Brookline Capital
Brookline Capital Markets, a division of Arcadia Securities, LLC
Brookline Capital Markets is a New York-based boutique investment bank serving life sciences, medical technology and diagnostics companies and SPACs, operating as a division of broker-dealer Arcadia Securities, LLC. Its small research team covers mainly biotechnology companies.
Company history
Three former Wall Street colleagues co-founded Brookline in 2013; in its early years it was a life sciences-focused family office before building an investment banking business. Managing partner William Buchanan Jr. was previously chief executive of Lazard Capital Markets. Brookline earlier operated as a division of CIM Securities and now works through Arcadia Securities. It sponsored the SPAC Brookline Capital Acquisition Corp., which merged with Apexigen in July 2022.
- 2013Brookline Capital Markets co-founded in New York
- 2022Sponsored SPAC Brookline Capital Acquisition Corp. merges with Apexigen
Research
Brookline's equity research concentrates on biotechnology and other healthcare companies and covered 41 companies as of January 2025, 83% of them rated Buy. Its salespeople distribute both proprietary and third-party research to institutional, family office and high-net-worth investors. Stocks are rated Buy (potential return above 15%), Hold (movement within 15%) or Sell (decline of more than 15%).
Coverage12M
- Stocks
- 6
- Ratings
- 6
- Price targets
- 0
- Upgrades
- 1
- Downgrades
- 2
- Initiations
- 0
- Reiterations
- 3
- Positive67%4
- Neutral33%2
- Negative0%0
Sectors
Ratings
Listing
Activity24M
Most covered24M
| Stock | Rating | Target |
|---|---|---|
 LSTALisata Therapeutics, Inc. | Hold | — |
 RNTXRein Therapeutics Inc. | Hold | — |
 VRCAVerrica Pharmaceuticals Inc. | Buy | — |
 CCCCC4 Therapeutics, Inc. | Buy | — |
 INTSIntensity Therapeutics, Inc. | Buy | — |
 MRNAModerna, Inc. | Buy | — |
 PALIPalisade Bio, Inc. | Buy | — |
 SCYXSCYNEXIS, Inc. | Buy | — |
Recent actions
| Stock | Rating action | Rating | Date |
|---|---|---|---|
| Moderna, Inc.MRNA | Reiterate | Buy | Aug 19 |
| SCYNEXIS, Inc.SCYX | Reiterate | Buy | Jul 31 |
| C4 Therapeutics, Inc.CCCC | Reiterate | Buy | Feb 23 |
| Lisata Therapeutics, Inc.LSTA | Downgrade | Buy →Hold | Jan 21 |
| Rein Therapeutics Inc.RNTX | Downgrade | Buy →Hold | Jan 21 |
| Verrica Pharmaceuticals Inc.VRCA | Upgrade | Hold →Buy | Dec 18, 2025 |
| Rein Therapeutics Inc.RNTX | Downgrade | Buy →Hold | Aug 19, 2025 |
| Intensity Therapeutics, Inc.INTS | Upgrade | Hold →Buy | Aug 12, 2025 |
| Lisata Therapeutics, Inc.LSTA | Reiterate | Buy | Jul 15, 2025 |
| Palisade Bio, Inc.PALI | Reiterate | Buy | May 13, 2025 |
| Verrica Pharmaceuticals Inc.VRCA | Downgrade | Buy →Hold | Oct 2, 2024 |
| DADaré Bioscience, Inc.DARE | Upgrade | Hold →Buy | May 15, 2024 |
References
- About the Firm - Brookline Capital Marketsbrooklinecapmkts.com
- Our Story - Brookline Capital Marketsbrooklinecapmkts.com
- Arcadia Securities, LLCarcadiasecurities.com
- Completed Transactions - Brookline Capital Marketsbrooklinecapmkts.com
- Brookline Capital Markets initiation on BioVie with rating definitions (March 2025)s205.q4cdn.com
- Nasdaq Equity Corporate Actions Alert #2022-190: Brookline Capital Acquisition Corp. and Apexigennasdaqtrader.com